Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish germ cell cancer group study

dc.contributor.authorGarcía del Muro Solans, Xavier
dc.contributor.authorMaroto, Pablo
dc.contributor.authorGuma, Josep
dc.contributor.authorSastre, Javier
dc.contributor.authorLópez Brea, Marta
dc.contributor.authorArranz, José A.
dc.contributor.authorLainez, Nuria
dc.contributor.authorSoto de Prado, Diego
dc.contributor.authorAparicio, Jorge
dc.contributor.authorPérez, Xavier
dc.contributor.authorGermà Lluch, José Ramón
dc.contributor.authorPiulats, Josep M.
dc.date.accessioned2024-12-02T17:25:54Z
dc.date.available2024-12-02T17:25:54Z
dc.date.issued2008
dc.date.updated2024-12-02T17:25:55Z
dc.description.abstractPurpose: To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma. Patients and methods: Untreated patients with pure seminoma of the testis after orchiectomy, with clinical stage IIA or IIB, were considered eligible for this prospective observational study. Chemotherapy consisted of either four cycles of cisplatin and etoposide or three cycles of cisplatin, etoposide, and bleomycin. Results: Between April 1994 and March 2003, 72 patients were entered onto the study at 26 participating centers. Eighteen patients had stage IIA disease, and 54 patients had stage IIB disease. Eighty-three percent of patients achieved complete response, and 17% achieved partial response with residual mass. After a median follow-up time of 71.5 months, six patients with stage IIB disease experienced relapse, and one of these patients died as a result of seminoma. Three patients experienced non-seminoma-related deaths (two died from a further esophageal carcinoma, and one died from an upper digestive hemorrhage). The estimated 5-year progression-free survival rates for patients with stage IIA or IIB disease were 100% and 87% (95% CI, 77.5% to 97%), respectively. Five-year progression-free and overall survival rates for the whole group were 90% (95% CI, 82% to 98%) and 95% (95% CI, 89% to 100%), respectively. Severe granulocytopenia and thrombocytopenia were observed in eight and two patients, respectively. Mild to moderate emesis, stomatitis, and diarrhea were the most common nonhematologic effects. Conclusion: Chemotherapy is a highly effective and well-tolerated treatment for patients with stage IIA or IIB seminoma and represents an available alternative that could avoid some of the serious late effects associated with radiotherapy. Further studies focusing on long-term toxicities of different treatment modalities are needed.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec590192
dc.identifier.issn0732-183X
dc.identifier.pmid18936476
dc.identifier.urihttps://hdl.handle.net/2445/216881
dc.language.isoeng
dc.publisherAmerican Society of Clinical Oncology
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1200/JCO.2007.15.9103
dc.relation.ispartofJournal of Clinical Oncology, 2008, vol. 26, num.33, p. 5416-5421
dc.relation.urihttps://doi.org/10.1200/JCO.2007.15.9103
dc.rights(c) American Society of Clinical Oncology, 2008
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationCisplatí
dc.subject.classificationQuimioteràpia
dc.subject.classificationTesticle
dc.subject.classificationCàncer
dc.subject.otherCisplatin
dc.subject.otherChemotherapy
dc.subject.otherTesticle
dc.subject.otherCancer
dc.titleChemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: A Spanish germ cell cancer group study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
138900.pdf
Mida:
104.73 KB
Format:
Adobe Portable Document Format